| Literature DB >> 35822200 |
Yu Hatano1, Nagisa Sawayama2, Hiroshi Miyashita3, Tomoyuki Kurashina4, Kenta Okada2, Manabu Takahashi2, Masatoshi Matsumoto5, Satoshi Hoshide6, Takahiro Sasaki7, Shuichi Nagashima8, Ken Ebihara2, Harushi Mori7, Kazuomi Kario6, Shun Ishibashi2.
Abstract
Context: The association between primary aldosteronism and obesity, especially its sex difference, remains unknown. Objective: To assess the association for each subtype of primary aldosteronism with obesity parameters including visceral adipose tissue and differences between sexes.Entities:
Keywords: aldosterone-producing adenoma; idiopathic hyperaldosteronism; obesity; primary aldosteronism; sex difference; visceral adipose tissue
Year: 2022 PMID: 35822200 PMCID: PMC9268741 DOI: 10.1210/jendso/bvac098
Source DB: PubMed Journal: J Endocr Soc ISSN: 2472-1972
Baseline characteristics of the patients with primary aldosteronism and matched controls
| APA (n = 42) | Control matched with APA (n = 168) |
| IHA (n = 68) | Control matched with IHA (n = 272) |
| |
|---|---|---|---|---|---|---|
| Women, n (%) | 22 (52.4) | 88 (52.4) | 1.000 | 42 (61.8) | 168 (61.8) | 1.000 |
| Age, mean ± SD, y | 50.9 ± 11.2 | 51.1 ± 10.8 | 0.934 | 51.8 ± 8.9 | 52.0 ± 8.8 | 0.897 |
| Current smokers, n (%) | 6 (14.3) | 24 (14.3) | 1.000 | 18 (26.5) | 58 (21.3) | 0.454 |
| Alcohol drinking, n (%) | 10 (23.8) | 40 (23.8) | 1.000 | 17 (25.0) | 68 (25.0) | 1.000 |
| Body mass index, mean ± SD, kg/m2 |
| 22.8 ± 3.5 |
|
| 22.7 ± 3.3 |
|
| Systolic blood pressure, mean ± SD, mm Hg | 144.1 ± 15.2 | 117.1 ± 11.3 |
| 142.0 ± 14.8 | 117.0 ± 12.1 |
|
| Diastolic blood pressure, mean ± SD, mm Hg | 87.7 ± 8.8 | 72.6 ± 8.9 |
| 88.1 ± 11.4 | 72.3 ± 8.9 |
|
| Fasting glucose, mean ± SD, mg/dL | 106.1 ± 26.3 (n = 31) | 98.5 ± 15.2 | 0.027 | 103.9 ± 19.1 (n = 57) | 97.8 ± 16.3 |
|
| Hemoglobin A1c, %, mean ± SD | 5.6 ± 1.1 (n = 37) | 5.6 ± 0.5 | 0.630 | 5.8 ± 0.7 (n = 62) | 5.6 ± 0.5 |
|
| Diabetes mellitus, n (%) | 9 (29.0) (n = 31) | 11 (6.5) |
| 11 (20.0) (n = 55) | 13 (4.8) |
|
| Triglyceride, median (IQR), mg/dL | 109.0 (71.0-141.0) (n = 35) | 84.5 (62.8-119.3) | 0.017 | 125.0 (100.0-166.0) (n = 57) | 84.5 (63.05-126.0) |
|
| HDL cholesterol, mean ± SD, mg/dL | 54.9 ± 15.3 (n = 34) | 68.1 ± 18.5 |
| 49.8 ± 13.7 (n = 57) | 69.7 ± 18.7 |
|
| LDL cholesterol, mean ± SD, mg/dL | 110.6 ± 30.5 (n = 33) | 127.6 ± 31.8 |
| 117.2 ± 27.7 (n = 56) | 126.8 ± 29.7 | 0.027 |
| eGFR, mean ± SD, mL/min/1.73 m2 | 82.6 ± 13.2 | 82.4 ± 10.8 | 0.930 | 82.9 ± 10.1 | 82.2 ± 9.0 | 0.573 |
| Serum sodium, mean ± SD, mEq/L |
| 141.4 ± 1.8 |
|
| 141.8 ± 1.8 | 0.096 |
| Serum potassium, mean ± SD, mEq/L |
| 4.1 ± 0.3 |
|
| 4.1 ± 0.3 |
|
| Serum uric acid, mean ± SD, mg/dL | 5.1 ± 1.5 | 5.2 ± 1.4 | 0.566 | 5.4 ± 1.3 | 5.1 ± 1.4 | 0.156 |
| Serum albumin, mean ± SD, mg/dL | 4.3 ± 0.3 | 4.5 ± 0.2 |
| 4.5 ± 0.4 | 4.5 ± 0.3 | 0.558 |
| Plasma aldosterone, median (IQR), pg/mL |
| – |
|
| – |
|
| Plasma renin activity, median (IQR), ng/mL/h |
| – |
|
| – |
|
| ARR, median (IQR) |
| – |
|
| – |
|
| Serum cortisol in the morning, median (IQR), μg/dL |
| – |
|
| – |
|
| Antihyperglycemic medication, n (%) | 5 (11.9) | 4 (2.4) | 0.021 | 8 (11.8) | 9 (3.3) |
|
| Lipid lowering medication, n (%) | 8 (19.0) | 13 (7.7) | 0.058 | 17 (25.0) | 23 (8.5) |
|
| Statin, n (%) | 7 (16.7) | 8 (4.8) | 0.019 | 13 (19.1) | 17 (6.2) |
|
| Potassium supplement, n (%) |
| 0 (0.0) |
|
| 0 (0.0) |
|
| Number of hypertensive medications, median (IQR) | 1.0 (1.0-2.0) | – |
| 1.0 (1.0-1.0) | – |
|
| Years to be hypertensive, median (IQR) |
| – |
|
| – |
|
| Medical history of CHD, n (%) | 0 (0.0) | 2 (1.2) | 1.000 | 1 (1.5) | 2 (0.7) | 1.000 |
| Medical history of stroke, n (%) | 3 (7.1) | 0 (0.0) |
| 1 (1.5) | 0 (0.0) | 0.453 |
| VAT areas, mean ± SD, cm2 | 111.9 ± 69.4 | 86.1 ± 55.7 |
| 1404.5 ± 70.9 | 89.0 ± 56.9 |
|
| SAT areas, mean ± SD, cm2 |
| 125.2 ± 60.2 | 0.207 |
| 125.2 ± 64.3 |
|
| VAT/SAT areas ratio, median (IQR) | 0.73 (0.44-1.15) | 0.62 (0.40-0.95) | 0.097 | 0.68 (0.50-1.06) | 0.62 (0.43-0.94) | 0.052 |
| Adrenal mass, n (%) |
| – | – |
| – | – |
Data are expressed as means ± SD, median (IQR), or counts (percentages). For the difference of characteristics, skewed variables were tested using 2-sample Wilcoxon rank-sum (Mann-Whitney) test; normal variables were tested using 2-sample t test; categorical variables were tested using χ 2 test. Statistical significance was defined by a 2-sided P value < 0.017 according to Bonferroni correction from multiple comparison test. Significant values are displayed in bold.
Abbreviations: ARR, plasma aldosterone to active renin ratio; CHD, coronary heart disease; eGFR, estimated glomerular filtration; HDL, high-density lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue.
Significant associations were found between APA vs IHA.
The association between the parameters of obesity and disease status
| Odds ratio (95% CI) |
| AUC (95% CI) | The difference of AUC |
| ||
|---|---|---|---|---|---|---|
| APA vs matched control | ||||||
| Model 1 | BMI (kg/m2) |
|
| – | – |
|
| Model 2 | VAT area (cm2) |
|
| 0.69 (0.61-0.77) |
|
|
| Model 3 | SAT area (cm2) | 1.23 (0.90-1.69) | 0.192 | 0.59 (0.49-0.68) | Reference | – |
| Model 4 | VAT area (cm2) |
|
| – | – | – |
| SAT area (cm2) | 0.87 (0.57-1.31) | 0.495 | ||||
| Model 5 | BMI (kg/m2) |
|
| – | – | – |
| Residual VAT area (cm2) | 1.18 (0.84-1.68) | 0.344 | ||||
| Residual SAT area (cm2) | 0.71 (0.50-1.02) | 0.067 | ||||
| IHA vs matched control | ||||||
| Model 1 | BMI (kg/m2) |
|
| – | – | – |
| Model 2 | VAT area (cm2) |
|
| 0.78 (0.71-0.83) | -0.01 (-0.06, 0.04) | 0.783 |
| Model 3 | SAT area (cm2) |
|
| 0.78 (0.72-0.83) | Reference | – |
| Model 4 | VAT area (cm2) |
|
| – | – | – |
| SAT area (cm2) | 1.42 (0.95, 2.12) | 0.086 | ||||
| Model 5 | BMI (kg/m2) |
|
| – | – | – |
| Residual VAT area (cm2) | 1.19 (0.87-1.63) | 0.286 | ||||
| Residual SAT area (cm2) | 0.94 (0.71-1.24) | 0.645 | ||||
| IHA vs APA | ||||||
| Model 1 | BMI (kg/m2) |
|
| – | – | – |
| Model 2 | VAT area (cm2) |
|
| 0.72 (0.62-0.81) | -0.01 (-0.10, 0.08) | 0.886 |
| Model 3 | SAT area (cm2) |
|
| 0.73 (0.63-0.82) | Reference | – |
| Model 4 | VAT area (cm2) | 1.69 (0.90-3.39) | 0.116 | – | – | – |
| SAT area (cm2) | 1.83 (1.02-3.49) | 0.051 | ||||
| Model 5 | BMI (kg/m2) |
|
| – | – | – |
| Residual VAT area (cm2) | 1.40 (0.88-2.27) | 0.159 | ||||
| Residual SAT area (cm2) | 1.38 (0.88-2.26) | 0.178 |
All models are adjusted for sex, age, current smoker, and drinking habit. Adjusted odds ratio (95% CIs) associated with a 1-SD increase of each obesity parameter are shown. For APA patients and the matched controls, the 1-SD increment of each obesity parameter is as follows: BMI, 3.65 kg/m2; VAT area, 59.40 cm2; SAT area, 62.03 cm2; residual VAT area, 34.89 cm2; and residual SAT area, 35.81 cm2. For IHA patients and the matched controls, the 1-SD increment of each obesity parameter is as follows: BMI, 3.88 kg/m2; VAT area, 63.85 cm2; SAT area, 71.21 cm2; residual VAT area, 34.98 cm2; and residual SAT area, 38.52 cm2. For APA and IHA patients, the 1-SD increment of each obesity parameter is as follows: BMI, 4.27 kg/m2; VAT area, 71.78 cm2; SAT area, 76.60 cm2; residual VAT area, 42.07 cm2; and residual SAT area, 44.39 cm2. Residuals of VAT and SAT areas were derived from Willett and Stampfer’s residual approach and were uncorrelated with BMI. Statistical significance was defined by a 2-sided P value < 0.017 according to Bonferroni correction from multiple comparison test. Significant values are displayed in bold.
Abbreviations: APA, aldosterone-producing adenoma; AUC, the area under the receiver operating characteristic curves; BMI, body mass index; CI, confidence interval; IHA, idiopathic hyperaldosteronism; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue.
The association between the parameters of obesity and disease status by sex
| Odds ratio (95% CI) |
| AUC (95% CI) | The difference of AUC |
| |||
|---|---|---|---|---|---|---|---|
| APA vs matched control | |||||||
| Men | Model 1 | BMI (kg/m2) |
|
| – | – |
|
| Model 2 | VAT area (cm2) |
|
| 0.77 (0.66-0.87) | 0.01 (-0.11, 0.12) | 0.895 | |
| Model 3 | SAT area (cm2) |
|
| 0.76 (0.64-0.87) | Reference |
| |
| Model 4 | VAT area (cm2) | 1.82 (0.93-3.54) | 0.080 | – | – | – | |
| SAT area (cm2) | 1.96 (0.99-3.88) | 0.054 | |||||
| Model 5 | BMI (kg/m2) |
|
| – | – | – | |
| Residual VAT area (cm2) | 1.21 (0.69-2.11) | 0.499 | |||||
| Residual SAT area (cm2) | 0.89 (0.51-1.57) | 0.691 | |||||
| Women | Model 1 | BMI (kg/m2) | 1.09 (0.69-1.72) | 0.721 | – | – | – |
| Model 2 | VAT area (cm2) | 1.19 (0.76-1.86) | 0.233 | 0.59 (0.46-0.72) | 0.02 (-0.17, 0.21) | 0.825 | |
| Model 3 | SAT area (cm2) | 0.78 (0.46-1.33) | 0.370 | 0.57 (0.44-0.70) | Reference | – | |
| Model 4 | VAT area (cm2) | 1.95 (0.96-4.00) | 0.066 | – | – | – | |
| SAT area (cm2) | 0.49 (0.23-1.04) | 0.065 | |||||
| Model 5 | BMI (kg/m2) | 1.11 (0.67-1.84) | 0.693 | – | – | – | |
| Residual VAT area (cm2) | 1.30 (0.78-2.18) | 0.310 | |||||
| Residual SAT area (cm2) | 0.52 (0.28-0.94) | 0.030 | |||||
| IHA vs matched control | |||||||
| Men | Model 1 | BMI (kg/m2) |
|
| – | – | – |
| Model 2 | VAT area (cm2) |
|
| 0.75 (0.64, 0.84) | -0.10 (-0.19, -0.01) | 0.037 | |
| Model 3 | SAT area (cm2) |
|
| 0.85 (0.76, 0.92) | Reference | – | |
| Model 4 | VAT area (cm2) | 1.25 (0.63-2.49) | 0.521 | – | – | – | |
| SAT area (cm2) |
|
| |||||
| Model 5 | BMI (kg/m2) |
|
| – | – | – | |
| Residual VAT area (cm2) | 0.67 (0.37-1.22) | 0.192 | |||||
| Residual SAT area (cm2) | 1.26 (0.75-2.09) | 0.383 | |||||
| Women | Model 1 | BMI (kg/m2) |
|
| – | – | – |
| Model 2 | VAT area (cm2) |
|
| 0.80 (0.73-0.87) | 0.05 (0.01, 0.10) | 0.024 | |
| Model 3 | SAT area (cm2) |
|
| 0.75 (0.68-0.82) | Reference | – | |
| Model 4 | VAT area (cm2) |
|
| – | – | – | |
| SAT area (cm2) | 0.84 (0.48-1.48) | 0.549 | |||||
| Model 5 | BMI (kg/m2) |
|
| – | – | – | |
| Residual VAT area (cm2) |
|
| |||||
| Residual SAT area (cm2) | 0.76 (0.52-1.12) | 0.172 | |||||
| IHA vs APA | |||||||
| Men | Model 1 | BMI (kg/m2) | 1.65 (0.86-3.56) | 0.158 | – | – | – |
| Model 2 | VAT area (cm2) | 1.51 (0.81-3.08) | 0.220 | 0.59 (0.42, 0.78) | 0.02 (-0.12, 0.19) | 0.755 | |
| Model 3 | SAT area (cm2) | 1.34 (0.68-2.95) | 0.419 | 0.57 (0.40, 0.73) | Reference | – | |
| Model 4 | VAT area (cm2) | 1.47 (0.68-3.43) | 0.344 | – | – | – | |
| SAT area (cm2) | 1.06 (0.45-2.63) | 0.898 | |||||
| Model 5 | BMI (kg/m2) | 1.61 (0.84-3.49) | 0.178 | – | – | – | |
| Residual VAT area (cm2) | 1.07 (0.55-2.11) | 0.834 | |||||
| Residual SAT area (cm2) | 0.84 (0.42-1.67) | 0.602 | |||||
| Women | Model 1 | BMI (kg/m2) |
|
| – | – | – |
| Model 2 | VAT area (cm2) |
|
| 0.80 (0.68, 0.91) | -0.03 (-0.15, 0.01) | 0.599 | |
| Model 3 | SAT area (cm2) |
|
| 0.83 (0.73, 0.93) | Reference | – | |
| Model 4 | VAT area (cm2) | 2.00 (0.85-5.43) | 0.139 | – | – | – | |
| SAT area (cm2) | 2.91 (1.15-8.74) | 0.035 | |||||
| Model 5 | BMI (kg/m2) |
|
| – | – | – | |
| Residual VAT area (cm2) | 2.01 (0.97-4.65) | 0.073 | |||||
| Residual SAT area (cm2) | 2.39 (1.16-5.63) | 0.027 |
All models are adjusted for age, current smoker, and drinking habit. Adjusted odds ratio (95% CIs) associated with a 1-SD increase of each obesity parameter are shown. For men among APA patients and the matched controls, the 1-SD increment of each obesity parameter is as follows: BMI, 2.89 kg/m2; VAT area, 57.94 cm2; SAT area, 54.52 cm2; residual VAT area, 42.58 cm2; and residual SAT area, 32.83 cm2. For women among APA patients and the matched controls, the 1-SD increment of each obesity parameter is as follows: BMI, 3.93 kg/m2; VAT area, 41.22 cm2; SAT area, 68.35 cm2; residual VAT area, 26.24 cm2; and residual SAT area, 38.46 cm2. For men among IHA patients and the matched controls, the 1-SD increment of each obesity parameter is as follows: BMI, 3.75 kg/m2; VAT area, 70.87 cm2; SAT area, 66.81 cm2; residual VAT area, 43.66 cm2; and residual SAT area, 38.04 cm2. For women among IHA patients and the matched controls, the 1-SD increment of each obesity parameter is as follows: BMI, 3.85 kg/m2; VAT area, 46.02 cm2; SAT area, 73.29 cm2; residual VAT area, 28.43 cm2; and residual SAT area, 38.91 cm2. For men among APA and IHA patients, the 1-SD increment of each obesity parameter is as follows: BMI, 3.39 kg/m2; VAT area, 70.67 cm2; SAT area, 73.69 cm2; residual VAT area, 47.20 cm2; and residual SAT area, 43.73 cm2. For women among APA and IHA patients, the 1-SD increment of each obesity parameter is as follows: BMI, 4.46 kg/m2; VAT area, 54.84 cm2; SAT area, 78.76 cm2; residual VAT area, 38.35 cm2; and residual SAT area, 45.21 cm2. Residuals of VAT and SAT areas were derived from Willett and Stampfer’s residual approach and were uncorrelated with BMI. Statistical significance was defined by a 2-sided P value < 0.017 according to Bonferroni correction from multiple comparison test. Significant values are displayed in bold.
APA, aldosterone-producing adenoma; AUC, the area under the receiver operating characteristic curves; BMI, body mass index; CI, confidence interval; IHA, idiopathic hyperaldosteronism; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue.